Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March PR Newswire DUBLIN, Feb. 27, 2013 DUBLIN, Feb. 27, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate in two upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . The conferences, presentation times and speakers include: *Cowen and Company 33rd Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2013 at 8:40 a.m. EST/1:40 p.m. GMT. Kathryn Falberg, executive vice president and chief financial officer, will provide a business update. *Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 12, 2013 at 9:00 a.m. EST/2:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide a business update. An archived version of each webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com . About Jazz Pharmaceuticals Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi ), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com . Website: http://www.jazzpharmaceuticals.com Contact: For Investors, Kathee Littrell, Vice President, Investor Relations, Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., +1-650-496-2717, For Media, Ami Knoefler, Executive Director, Corporate Communications, Jazz Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., +1-650-496-2947
Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March
Press spacebar to pause and continue. Press esc to stop.